Sandoz is maintaining its full-year earnings guidance for 2022 despite reporting 8% top-line growth at constant currencies for the first three months of the year, alongside a sizeable jump in its operating profit and core operating profit.
While the Novartis division’s promising first-quarter financials were evidence of its business dynamics having “really stabilized,” Sandoz commented, they also reflected a comparison with a weaker first quarter of 2021 and included